Heart Failure Death Rates Higher in Females than Males

CAITLIN WILLIAMS | July 17, 2018

article image
Heart failure is a common cause of morbidity and mortality, despite progress made over the past 10 years, more than 6 million Americans live with heart failure, and over 900,000 new cases are diagnosed each year. There are known sex-based differences in risk factors, presentation, and management of heart disease. A recent study sought to increase understanding of how sex differences relate to heart failure incidence, mortality, hospital admission and comorbidities (the presence of two chronic diseases).

Spotlight

Merck Consumer Health Care

Merck is a global pharmaceutical and chemical company with a history that began in 1668, and a future shaped by around 40,000 employees in 64 countries. With the acquisition of Millipore in July 2010, a global leader in the life science tools market, pro forma revenues totaled around EUR 8.9 billion in 2009. Innovations made possible by entrepreneurial employees characterize the company’s success. Merck's operating activities are combined under the umbrella of Merck KGaA, in which the Merck family indirectly holds an interest of approximately 70%. The remaining 30% is publicly traded.

OTHER ARTICLES

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

The Future of Pharma Beyond Blockbusters

Article | February 17, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | February 17, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Comparing HydroxyChloroquine Trials

Article | February 17, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Spotlight

Merck Consumer Health Care

Merck is a global pharmaceutical and chemical company with a history that began in 1668, and a future shaped by around 40,000 employees in 64 countries. With the acquisition of Millipore in July 2010, a global leader in the life science tools market, pro forma revenues totaled around EUR 8.9 billion in 2009. Innovations made possible by entrepreneurial employees characterize the company’s success. Merck's operating activities are combined under the umbrella of Merck KGaA, in which the Merck family indirectly holds an interest of approximately 70%. The remaining 30% is publicly traded.

Events